IVVD, US00534A1025

Invivyd stock: Q3 revenue rises as net loss widens

Published on 11/19/2026 at 02:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Invivyd stock is in focus after a third-quarter update that lifted product revenue but showed a wider net loss. Management expects key trial data soon.

Invivyd advances antibody pipeline

  • Invivyd expects interim data from the DECLARATION Phase 3 study of VYD2311 imminently after discussions with the U.S. Food and Drug Administration.
  • The company appointed Chairman Marc W. Elia as chief executive officer and started the FLINTLOCK Phase 2 study for Long COVID and Post-Vaccination Syndrome.
  • Invivyd ended September with 126.4 million US dollars in cash and cash equivalents.
IVVD, US00534A1025, Illustration mit AI erstellt.

Invivyd reported third-quarter 2026 results on November 16, covering the period ended September 30. The biopharmaceutical company said PEMGARDA net product revenue increased from the year-earlier quarter, while higher research and commercial spending widened the net loss. The update also put a new chief executive in place and set the next clinical milestone for VYD2311.

Invivyd said PEMGARDA net product revenue reached 15.4 million US dollars, compared with 13.1 million US dollars in the third quarter of 2025. The company attributed the increase to higher patient demand. Net loss widened to 33.5 million US dollars from 10.5 million US dollars, while research and development expense rose to 18.7 million US dollars from 8.0 million US dollars.

Regulatory milestone moves closer

Invivyd expects interim data from the DECLARATION Phase 3 study of VYD2311, also known as ibramvibart, imminently. The company said discussions with the U.S. Food and Drug Administration helped refine its planned accelerated approval approach. DECLARATION is intended to support a potential Biologics License Application and will continue as a confirmatory study collecting symptomatic COVID-19 events.

The company also reported positive topline results from the LIBERTY Phase 3 study. VYD2311 met its primary and secondary endpoints against an mRNA-based COVID-19 vaccine, according to Invivyd, and co-administration did not interfere with vaccine-induced neutralizing antibody titers. Invivyd has started FLINTLOCK, a Phase 2 study designed to evaluate VYD2311 in adults with Long COVID or Post-Vaccination Syndrome.

Leadership and cash position

Chairman Marc W. Elia became chief executive officer in September. Invivyd ended the third quarter with 126.4 million US dollars in cash and cash equivalents. The company plans a Medical and Commercial Investor Event in the first half of 2027 to discuss commercial preparations for VYD2311 and early institutional demand.

Invivyd's antibody business

Invivyd develops monoclonal antibodies intended to prevent or treat serious viral infectious diseases, initially focusing on SARS-CoV-2. Its pipeline includes PEMGARDA, the VYD2311 COVID-19 candidate and VMS063, an investigational measles antibody. The company is headquartered in New Haven, Connecticut, and its shares trade on Nasdaq.

Invivyd company facts

  • Company: Invivyd, Inc.
  • ISIN: US00534A1025
  • Ticker: IVVD
  • Home exchange: Nasdaq
  • Headquarters: New Haven, Connecticut, United States
  • Sector: Biopharmaceuticals

Invivyd's results add to the biotechnology activity tracked in the S&P 500 market environment.

More news and analyses on Invivyd stock.

Disclaimer...
en | US00534A1025 | IVVD | boerse | 70533305 | bgmi